ONK Therapeutics signs option license agreements to strengthen NK cell therapy pipeline Dec. 18, 2020
Discovery and preclinical evaluation of a new sGC stimulator for hypertension treatment Dec. 18, 2020
Interim phase II data for darolutamide demonstrate efficacy in advanced AR-positive TNBC Dec. 17, 2020
RSS